| First Author | Steidinger TU | Year | 2011 |
| Journal | J Neurochem | Volume | 116 |
| Issue | 3 | Pages | 334-41 |
| PubMed ID | 21091473 | Mgi Jnum | J:170263 |
| Mgi Id | MGI:4946156 | Doi | 10.1111/j.1471-4159.2010.07112.x |
| Citation | Steidinger TU, et al. (2011) A neuroprotective role for angiogenin in models of Parkinson's disease. J Neurochem 116(3):334-41 |
| abstractText | We previously observed marked down-regulation of the mRNA for angiogenin, a potent inducer of neovascularization, in a mouse model of Parkinson's disease (PD) based on over-expression of alpha-synuclein. Angiogenin has also been recently implicated in the pathogenesis of amyotrophic lateral sclerosis. In this study, we confirmed that mouse angiogenin-1 protein is dramatically reduced in this transgenic alpha-synuclein mouse model of PD, and examined the effect of angiogenin in cellular models of PD. We found that endogenous angiogenin is present in two dopamine-producing neuroblastoma cell lines, SH-SY5Y and M17, and that exogenous angiogenin is taken up by these cells and leads to phosphorylation of Akt. Applied angiogenin protects against the cell death induced by the neurotoxins 1-methyl-4-phenylpyridinium and rotenone and reduces the activation of caspase 3. Together our data supports the importance of angiogenin in protecting against dopaminergic neuronal cell death and suggests its potential as a therapy for PD. |
